

10 July 2019

## **Positive results from Clinical Study with ICORES**

*Iconovo AB (publ) together with Amneal Pharmaceuticals Company GmbH and CBC Corporation India Pvt Ltd (fully owned subsidiary of CBC Co. Ltd, Japan) have carried out a clinical pharmacokinetic study to compare Iconovo's generic product, ICORES budesonide/formoterol, to the original, Symbicort® Turbuhaler®. The plan for this study was announced in a PM dated 8 Nov 2018.*

This pilot study, in line with its primary objective, demonstrated that the ICORES dry powder inhaler device functioned as intended clinically. The device delivered the appropriate quantity of the formulation during laboratory testing as well as in the clinical testing as evidenced by the plasma levels in study subjects. No accidental overdosing was noticed in the subjects.

The results of the study, which had a single-dose cross-over design with 29 healthy volunteers, showed excellent correspondence with regards to budesonide and slightly higher values for ICORES with regards to formoterol. The results will be used as important information in the remaining development work, to fully match ICORES to the original product.

“We are happy that we now for the first time can demonstrate that ICORES together with the formulation also developed by Iconovo, work in humans. The results from the clinical study was above our expectations, and I now look forward to start the final phase of the development project”, says Orest lastow, CEO of Iconovo.